Chart of the Day: Summit Therapeutics (SMMT)
Keep an eye on Summit Therapeutics (SMMT). Co-CEO and Executive Chairman Robert Duggan just bought $75 million worth of SMMT at an average price of $22.70 a share. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development,...










